Injury Center Funding Opportunity Announcements (FOAs)

CE10-002: Unintentional Poisoning from Prescription Drug Overdose in Adults

Initial Fiscal Year: 2010
Program: ERPO
FOA Number: CE10-002
FOA Title: Unintentional Poisoning from Prescription Drug Overdose in Adults


This funding opportunity announcement encourages research that will build the scientific base for the prevention of unintentional poisonings from drug overdoses in the adult population (ages 15 to 64 years). It solicits proposals from organizations to conduct exploratory/developmental research that evaluates novel approaches to drug overdose prevention and addresses the NCIPC’s research agenda priorities related to unintentional poisoning. It is meant to engage professionals from a wide spectrum of disciplines including epidemiology, community medicine, pharmacology, biostatistics, public policy, public health law, justice, and behavioral and social sciences.

Program Description

NCIPC is soliciting investigator-initiated research that will expand and advance our understanding of what works to prevent unintentional drug overdoses associated with prescription drugs. Applications are sought that will perform one (or more) of the following activities:

1. Evaluate risk management strategies (“RiskMAPs”) employed by pharmaceutical companies after a drug comes on the market. This might include evaluation of the surveillance measures put in place to detect misuse and abuse or overmedication of opioids and/or evaluation of the private sector’s responses when surveillance indicates a potential problem.

2. Evaluate the effectiveness of actions taken by the Food and Drug Administration (short of removing the product from the market) to correct problems associated with overdoses from controlled substances, including opioids, once they reach the market. This might include evaluation of “black box” warnings placed on drugs, restriction of the indications or circumstances under which a drug can be used, physician education, or other control measures.

3. Evaluate the effectiveness of economic-based interventions that identify potential abusers and restrict their accessibility to drugs with overdose potential, through insurance mechanisms that require prescriptions from specified providers or pharmacies. This might include evaluation of the Patient Restriction and Review programs of state Medicaid agencies or similar programs instituted by private insurers.

4. Evaluate programs that provide naloxone as an antidote to high risk persons who have been prescribed opioids and have the potential of abuse, unintentional misuse, or overdose. This may include community trials of such programs that produce data on both the risks and benefits of making naloxone routinely available for such patients.

5. Conduct opportunistic evaluations of imminent changes in policies or environments that could influence the rising rate of prescription drug overdoses among adults, for example “natural experiments,” legislative changes, state laws adopted, changes in physician prescribing practices, physician training and education initiatives, etc.

6. Conduct studies that can inform the ongoing policy debate on prescription drug overdose prevention, for example small experimental studies, secondary data analyses in a state or county, cost-effectiveness analyses of promising interventions, modeling health systems change, health impact assessments, simulations of policy effects, or macro-level policy analyses).

Special Considerations:

1. If an RFA is developed and published, NCIPC will initiate a conference call to clarify the intent of the RFA and assist potential applicants.

2. Annual progress meetings between grantees and NCIPC will be required, so travel money must be budgeted.

3. Applicants, or their research partners, will be required to include evidence of prior experience conducting medical, pharmaceutical, drug abuse or injury prevention evaluation studies through publications or technical reports they produced in an appendix to the application.

4. Governmental and academic applicants are encouraged to work in partnership with each other, where possible, to strengthen their overall approach.

5. Preference will be given to applicants from areas that have above-average rates of mortality from drug poisoning that is unintentional or of undetermined intent. Applicants are expected to address the potential this research would have in reducing morbidity and mortality rates in similar areas of the country that also have above-average rates.

Awarded Projects

Project Title: Unintentional Prescription Opioid Poisoning Deaths in Connecticut and Rhode Island
Grant Number: CE001846
Project Period: 9/1/20108/31/2012

Project Title: Evaluation of the Washington State Guidelines on Opioid Dosing for Chronic Pain
Grant Number: CE001850
Project Period: 9/1/20108/31/2012